CGEM · Cullinan Therapeutics, Inc.

NasdaqHealthcareBiotechnology

Cullinan Therapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Developing Therapies For Autoimmune Diseases And Cancer. Its Development Pipeline Comprises The Following Drug Candidates: Cln-978, A Cd19xcd3 Bispecific T Cell Engager That Is Being Developed For Autoimmune Diseases; Cln-049, A Flt3xcd3 Bispecific T Cell Engager Being Evaluated In An Ongoing Clinical Trial In Patients With Relapsed/Refractory Acute Myeloid Leukemia (Aml) Or Myelodysplastic Syndrome (Mds); Velinotamig, A Bcmaxcd3 Bispecific T Cell Engager Being Developed To Counter Autoimmune Diseases; And Zipalertinib, Being Developed As A Treatment For Non-Small Cell Lung Cancer. Additionally, The Company Is Developing Several Preclinical Programs In Autoimmune Diseases And Oncology.

HealthcareNasdaqUS

FLOAT

53.5M

FREE FLOAT %

83%

SHARES O/S

64.4M

MARKET CAP

$924.8M

EXCHANGE

Nasdaq

COUNTRY

CGEM Catalyst History

No catalysts recorded for CGEM yet

Day Trader Sniper hasn't classified a publishable catalyst for CGEM yet. New events appear here as they're scored.

Be early on the next CGEM spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

CGEM · Cullinan Therapeutics, Inc.

CGEM Catalyst History

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.